Incyte Q4 2024 revenue $1.18B (+16% YoY), guides 2025 Jakafi $2.93-2.98B, Opzelura $630-670M

INCYTE CORP

2024-FY EPS reported $0.15 revenue$4,241,217,000

Q4 total revenues $1.18B (+16% YoY); full year $4.24B (+15%). GAAP diluted EPS $1.02 (Q4), $0.15 (FY); Non-GAAP $1.43 (Q4), $1.08 (FY).
Jakafi net revs Q4 $773M (+11% YoY), FY $2.79B (+8%); Opzelura Q4 $162M (+48%), FY $508M (+50%).
FY2025 guidance: Jakafi $2,925-2,975M; Opzelura $630-670M; other oncology $415-455M.
Pipeline catalysts: Niktimvo launched; ruxolitinib XR bioequivalence met, submission by year-end 2025; four pivotal readouts in 2025.
Cash and securities $2.2B at Dec 31, 2024, down from $3.7B due to $2B share repurchase and $783M Escient acquisition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.